Wall Street analysts expect that Sientra Inc (NASDAQ:SIEN) will report ($0.67) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Sientra’s earnings, with the lowest EPS estimate coming in at ($0.72) and the highest estimate coming in at ($0.64). Sientra posted earnings per share of ($0.74) in the same quarter last year, which indicates a positive year over year growth rate of 9.5%. The company is expected to issue its next quarterly earnings results on Tuesday, November 6th.

On average, analysts expect that Sientra will report full-year earnings of ($2.93) per share for the current year, with EPS estimates ranging from ($3.04) to ($2.85). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.18) per share, with EPS estimates ranging from ($2.55) to ($1.77). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover Sientra.

Sientra (NASDAQ:SIEN) last announced its quarterly earnings results on Tuesday, August 7th. The medical instruments supplier reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.04). The firm had revenue of $17.55 million for the quarter, compared to analyst estimates of $15.30 million. Sientra had a negative net margin of 131.16% and a negative return on equity of 151.47%.

A number of analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Sientra from a “sell” rating to a “hold” rating in a research note on Saturday. BidaskClub lowered shares of Sientra from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Canaccord Genuity boosted their price target on shares of Sientra from $19.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Stephens restated a “buy” rating and set a $30.00 target price on shares of Sientra in a research note on Thursday, August 9th. Finally, Stifel Nicolaus upped their target price on shares of Sientra from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $22.50.

NASDAQ SIEN traded up $0.81 during trading hours on Thursday, reaching $24.23. The company had a trading volume of 9,237 shares, compared to its average volume of 298,390. Sientra has a 1-year low of $8.79 and a 1-year high of $26.79. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.06 and a quick ratio of 2.63. The stock has a market capitalization of $698.75 million, a P/E ratio of -8.50 and a beta of -0.80.

In related news, CEO Jeffrey M. Nugent sold 1,852 shares of the company’s stock in a transaction that occurred on Friday, August 31st. The shares were sold at an average price of $24.90, for a total transaction of $46,114.80. Following the sale, the chief executive officer now directly owns 297,999 shares in the company, valued at $7,420,175.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 31.00% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in SIEN. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Sientra during the second quarter worth approximately $160,000. Commonwealth Equity Services LLC purchased a new stake in shares of Sientra during the second quarter worth approximately $210,000. MetLife Investment Advisors LLC purchased a new stake in shares of Sientra during the second quarter worth approximately $226,000. Barclays PLC increased its stake in shares of Sientra by 133.7% during the first quarter. Barclays PLC now owns 31,521 shares of the medical instruments supplier’s stock worth $304,000 after buying an additional 18,033 shares during the period. Finally, Rhumbline Advisers boosted its holdings in Sientra by 55.6% in the second quarter. Rhumbline Advisers now owns 21,621 shares of the medical instruments supplier’s stock valued at $422,000 after purchasing an additional 7,725 shares in the last quarter. Hedge funds and other institutional investors own 89.21% of the company’s stock.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Read More: Understanding Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Sientra (SIEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.